GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » VIA Pharmaceuticals Inc (GREY:VIAP) » Definitions » Shiller PE Ratio

VIA Pharmaceuticals (VIA Pharmaceuticals) Shiller PE Ratio : (As of Jun. 21, 2024)


View and export this data going back to 1998. Start your Free Trial

What is VIA Pharmaceuticals Shiller PE Ratio?

Shiller PE for Stocks: The True Measure of Stock Valuation


VIA Pharmaceuticals Shiller PE Ratio Historical Data

The historical data trend for VIA Pharmaceuticals's Shiller PE Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

VIA Pharmaceuticals Shiller PE Ratio Chart

VIA Pharmaceuticals Annual Data
Trend Dec01 Dec02 Dec03 Dec04 Dec05 Dec06 Dec07 Dec08 Dec09 Dec10
Shiller PE Ratio
Get a 7-Day Free Trial Premium Member Only Premium Member Only -0.18 - - - -

VIA Pharmaceuticals Quarterly Data
Mar06 Jun06 Sep06 Dec06 Mar07 Jun07 Sep07 Dec07 Mar08 Jun08 Sep08 Dec08 Mar09 Jun09 Sep09 Dec09 Mar10 Jun10 Sep10 Dec10
Shiller PE Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Competitive Comparison of VIA Pharmaceuticals's Shiller PE Ratio

For the Biotechnology subindustry, VIA Pharmaceuticals's Shiller PE Ratio, along with its competitors' market caps and Shiller PE Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


VIA Pharmaceuticals's Shiller PE Ratio Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, VIA Pharmaceuticals's Shiller PE Ratio distribution charts can be found below:

* The bar in red indicates where VIA Pharmaceuticals's Shiller PE Ratio falls into.



VIA Pharmaceuticals Shiller PE Ratio Calculation

For Shiller PE Ratio, the earnings of the past 10 years are inflation-adjusted and averaged. The result is used for P/E calculation. Since it looks at the average over the last 10 years, the Shiller PE Ratio is also called PE10.

The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The same calculation is applied here to individual companies.

VIA Pharmaceuticals's E10 for the quarter that ended in Dec. 2010 is calculated as:

For example, VIA Pharmaceuticals's adjusted earnings per share data for the three months ended in Dec. 2010 was:

Adj_EPS=Earnings per Share (Diluted)/CPI of Dec. 2010 (Change)*Current CPI (Dec. 2010)
=-0.12/92.4740*92.4740
=-0.120

Current CPI (Dec. 2010) = 92.4740.

VIA Pharmaceuticals Quarterly Data

Earnings per Share (Diluted) CPI Adj_EPS
200103 -11.547 74.341 -14.364
200106 -13.646 75.100 -16.803
200109 -13.650 75.227 -16.780
200112 -11.550 74.552 -14.327
200203 -11.547 75.438 -14.155
200206 -12.596 75.902 -15.346
200209 -11.547 76.366 -13.983
200212 -16.361 76.324 -19.823
200303 -46.050 77.716 -54.795
200306 -4.500 77.505 -5.369
200309 -6.300 78.138 -7.456
200312 -2.750 77.758 -3.270
200403 -3.300 79.066 -3.860
200406 -2.700 80.037 -3.120
200409 -1.950 80.121 -2.251
200412 -3.900 80.290 -4.492
200503 -4.350 81.555 -4.932
200506 -5.550 82.062 -6.254
200509 -3.750 83.876 -4.134
200512 -4.145 83.032 -4.616
200603 -4.200 84.298 -4.607
200606 -5.020 85.606 -5.423
200609 -4.600 85.606 -4.969
200612 -5.210 85.142 -5.659
200703 -13.050 86.640 -13.929
200706 -1.990 87.906 -2.093
200709 -0.270 87.964 -0.284
200712 -0.262 88.616 -0.273
200803 -0.300 90.090 -0.308
200806 -0.270 92.320 -0.270
200809 -0.250 92.307 -0.250
200812 -0.210 88.697 -0.219
200903 -0.220 89.744 -0.227
200906 -0.220 91.003 -0.224
200909 -0.400 91.120 -0.406
200912 -0.210 91.111 -0.213
201003 -0.140 91.821 -0.141
201006 -0.110 91.962 -0.111
201009 -0.100 92.162 -0.100
201012 -0.120 92.474 -0.120

Add all the adjusted EPS together and divide 10 will get our E10.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.


VIA Pharmaceuticals  (GREY:VIAP) Shiller PE Ratio Explanation

Compared with the regular PE Ratio, which works poorly for cyclical businesses, the Shiller PE Ratio smoothed out the fluctuations of profit margins during business cycles. Therefore it is more accurate in reflecting the valuation of the company.

If a company has consistent business performance, the Shiller PE Ratio should give similar results to regular PE Ratio.

Compared with the PS Ratio, the Shiller PE Ratio makes the comparison between different industries more meaningful.


Be Aware

Shiller PE Ratio assumes that over the long term, businesses and profitability revert to their means. If a company's business model does not work in the future compared with the past, Shiller PE Ratio and PS Ratio will give false valuations.


VIA Pharmaceuticals Shiller PE Ratio Related Terms

Thank you for viewing the detailed overview of VIA Pharmaceuticals's Shiller PE Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.


VIA Pharmaceuticals (VIA Pharmaceuticals) Business Description

Traded in Other Exchanges
N/A
Address
750 Battery Street, Suite 330, San Francisco, CA, USA, 94111
VIA Pharmaceuticals Inc is a development stage biotechnology company focuses on the development of small-molecule drugs to treat cardiovascular and metabolic diseases.
Executives
Fred B Craves director 750 BATTERY ST, STE 600, SAN FRANCISCO CA 94111
Bay City Capital Fund Iv, L.p. 10 percent owner 750 BATTERY STREET, SUITE 400, SAN FRANCISCO CA 94111
Bay City Capital Management Iv Llc 10 percent owner 750 BATTERY STREET, SUITE 400, SAN FRANCISCO CA 94111
Bay City Capital Fund Iv Co Invesment Fund Lp 10 percent owner 750 BATTERY ST STE 400, SAN FRANCISCO CA 94111
Bay City Capital Llc 10 percent owner 750 BATTERY STREET STE 400, SAN FRANCISCO CA 94111
Douglas B Given director C/O NEORX CORP, 410 WEST HARRISON ST, SEATTLE WA 98119
Karen Steil Wright officer: V.P. ? Finance, Controller 750 BATTERY STREET, SUITE 330, SAN FRANCISCO CA 94111
Lawrence Kenneth Cohen director, officer: CEO and President 750 BATTERY STREET, SUITE 330 SAN FRANCISCO CA 94111
Richard L Anderson director 14031 216TH WAY NE, WOODINVILLE WA 98072
Mark Bagnall director 3876 BAY CENTER PLACE, HAYWARD CA 94545
Rebecca Taub officer: SVP, Research & Development 750 BATTERY STREET, SUITE 330, SAN FRANCISCO CA 94111
Adeoye Y Olukotun officer: Chief Medical Officer 3621 SOUTH STATE ST, 695 KMS PL, ANN ARBOR MI 48108
Deerfield Special Situations Fund International Ltd 10 percent owner, other: Possible Member of 10% Group BISON COURT, ROAD TOWN, TORTOLA D8 -
Deerfield Special Situations Fund, L.p. 10 percent owner, other: Possible Member of 10% Group 780 3RD AVENUE, 37TH FLOOR, NEW YORK NY 10017
James E Flynn 10 percent owner, other: Possible Member of 10% Group 780 THIRD AVENUE, 37TH FLOOR, NEW YORK NY 10017

VIA Pharmaceuticals (VIA Pharmaceuticals) Headlines

From GuruFocus